{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer+%28Diagnosis%29&page=2", "query": { "condition": "Gastric Cancer (Diagnosis)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 984, "total_pages": 99, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer+%28Diagnosis%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer+%28Diagnosis%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T18:38:47.509Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003192", "title": "Aminocamptothecin in Treating Patients With Stomach Cancer or Cancer of the Esophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "aminocamptothecin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "1998-03", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 7, "location_summary": "Chicago, Illinois • Decatur, Illinois • Peoria, Illinois + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003192" }, { "nct_id": "NCT00001228", "title": "Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Islet Cell Adenoma", "Zollinger Ellison Syndrome" ], "interventions": [ { "name": "Interferon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "1988-10-25", "completion_date": "2007-09-06", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001228" }, { "nct_id": "NCT02850536", "title": "CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Metastases" ], "interventions": [ { "name": "anti-CEA CAR-T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Roger Williams Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2017-02-01", "completion_date": "2021-09-17", "has_results": false, "last_update_posted_date": "2021-10-21", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 2, "location_summary": "Aurora, Colorado • Providence, Rhode Island", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02850536" }, { "nct_id": "NCT00096707", "title": "Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Breast Cancer", "Pancreatic Cancer", "Head and Neck Cancer", "Gastric Cancer" ], "interventions": [ { "name": "2-deoxy-D-glucose (2DG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Threshold Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2004-02", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2009-04-29", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 3, "location_summary": "Miami, Florida • Indianapolis, Indiana • San Antonio, Texas", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096707" }, { "nct_id": "NCT03042780", "title": "FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor", "Pancreatic Cancer", "Neuroendocrine Carcinomas of Pancreas", "Islet Cell Carcinoma" ], "interventions": [ { "name": "FOLFIRINOX", "type": "DRUG" }, { "name": "Granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-02-01", "completion_date": "2018-09-07", "has_results": true, "last_update_posted_date": "2020-11-27", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03042780" }, { "nct_id": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCAGN01949", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-10-09", "completion_date": "2019-09-17", "has_results": true, "last_update_posted_date": "2022-09-27", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03241173" }, { "nct_id": "NCT04592913", "title": "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Neoplasms", "Esophagogastric Junction" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "FLOT chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "200 Years", "sex": "ALL", "summary": "18 Years to 200 Years" }, "enrollment_count": 957, "start_date": "2020-11-17", "completion_date": "2027-09-27", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Sylmar, California + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04592913" }, { "nct_id": "NCT00957424", "title": "Acceptability of Less Harmful Alternatives to Cigarettes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bladder Cancer", "Cervical Cancer", "Esophageal Cancer", "Gastric Cancer", "Head and Neck Cancer", "Kidney Cancer", "Leukemia", "Liver Cancer", "Lung Cancer", "Pancreatic Cancer", "Tobacco Use Disorder" ], "interventions": [ { "name": "telephone-based intervention", "type": "BEHAVIORAL" }, { "name": "nicotine replacement therapy", "type": "DRUG" }, { "name": "informational intervention", "type": "OTHER" }, { "name": "internet-based intervention", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 67, "start_date": "2009-06", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00957424" }, { "nct_id": "NCT04430738", "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Carcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Esophageal Adenocarcinoma", "Cholangiocarcinoma", "Gallbladder Carcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-09-15", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04430738" }, { "nct_id": "NCT05477576", "title": "Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "GEP-NET", "Gastroenteropancreatic Neuroendocrine Tumor", "Gastroenteropancreatic Neuroendocrine Tumor Disease", "Neuroendocrine Tumors", "Carcinoid", "Carcinoid Tumor", "Pancreatic NET" ], "interventions": [ { "name": "RYZ101", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Octreotide", "type": "DRUG" }, { "name": "Lanreotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RayzeBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 343, "start_date": "2022-03-24", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-07T18:38:47.509Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 27 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05477576" } ] }